This gift keeps giving

Article Excerpt

ELI LILLY & CO., $778.62, is still a buy. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares outstanding: 949.3 million; Market cap: $739.2 billion; Dividend yield: 0.8%) now plans to test its popular weight-loss drug Zepbound as a treatment for alcohol and drug addiction. The news comes as the body of evidence increasingly suggests Zepbound and other GLP-1 weight-loss drugs can help people with substance abuse disorders. Indeed, several retrospective studies already suggest an association between GLP-1 treatments and lower risks of alcohol and opioid abuse. These studies show promise, and Eli Lilly will be the first pharmaceutical firm to conduct clinical trials specifically focused on addiction treatment. The company’s planned studies are set to begin next year. Eli Lilly is a buy. buy…